Currently, people 50 years of age and older, vulnerable individuals and leading health professionals are entitled to a booster dose of the vaccine. The Joint Vaccine and Immunization Committee (JCVI) has now announced that the booster (third) dose will be extended to another group.
The recommendation comes at a time when practice data show that the booster dose of the vaccine provides more than 90% protection against symptomatic COVID-19 in people 50 years of age and older.
“Booster doses for more vulnerable adults and second doses for 16- to 17-year-olds are an important way to increase our protection against covia and serious illnesses.” Wei Shen Lim, head of the Kovit vaccine at JCVI, said.
“These benefits will help extend our security until 2022.” Added.
The UK booster vaccine uses vaccines from Pfizer / BioNTech and Moderna, and people can get a third dose six months after the second dose.
Practical study shows that protection against symptomatic disease after a booster dose is 93.1 percent in those who received the first estrogen vaccine and 94 percent in those who received the Pfizer vaccine earlier.
JCVI added that greater protection against the acute course of the disease is expected after the booster dose.
However, the team refused to recommend booster doses for people under the age of 40 because the researchers did not find significant evidence of a decrease in cov- eral safety after the original doses were given to this age group.
“Passionate coffee fanatic. Social media lover. Twitter expert. Extreme music practitioner. Zombie junkie. Hardcore travel specialist.”